This toolkit was last updated 9/14/2022 and is no longer being reviewed for accuracy and updates. Resources should be used with caution, as content may be outdated.
SIDP has developed a COVID-19 Oral Antiviral Toolkit in conjunction with National Alliance of State Pharmacy Associations (NASPA). The content of this toolkit is informed by the experiences of pharmacists with expertise in the treatment and prevention of COVID-19 and who practice in diverse settings (community, outpatient, inpatient) and diverse patient populations (pediatrics, adults, immunocompromised).
SIDP member, Sohail Azam, PharmD (left) with a physician colleague
Outpatient COVID-19 Oral Antiviral Decision Tree
Example Order Sets and Forms
Excerpt from Outpatient COVID-19 Oral Antiviral Therapy Decision Tree
COVID-19 Oral Antiviral Product Comparison Table
Register to Access Toolkit Resources
SIDP will not share any contact information provided with any third party and
will only contact registered resource users with information pertaining to educational resources
Once you have signed up as a Registered Resource User, access the toolkit resources using the link below!
Note, SIDP members can also access the toolkit at the link below.
Please keep in mind that information, data, and availability of oral antivirals in COVID-19 is constantly evolving. Use of SIDP guidelines and/or toolkits are intended as recommendations. Use does not supersede clinical judgement based on the assessment of an individual patient by an individual practitioner. The recommendations reflect the best available evidence at the time of publication and are not the sole resource for patient care management and/or an exclusive source of action.
SIDP COVID-19 Oral Antiviral Toolkit Taskforce Members
Special thanks to the following SIDP members for volunteering their time and efforts to the development of this toolkit:
SIDP member, Regina Orbach, PharmD (right), discussing COVID-19 oral antivirals with a pharmacy post-graduate trainee (left)
This toolkit was sponsored by an unrestricted medical grant from Merck.
Release Date: 9/14/2022